Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
The company has posted net loss of Rs. 99.54 crores for the period ended March 31, 2020
Dr. Reddy's has the rights to distribute 250mn doses in India
India sales grew 23.5% YoY with consolidation of Wockhardt products
A total quantum of more than 4.39 crore doses was also available for direct procurement by the states as well as private hospitals in the month of May 2021
Aarti Drugs has reported total income of Rs.2159.30 crores during the 12 months period ended March 31, 2021
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
Financial support is being provided as a grant from the Government of India
Subscribe To Our Newsletter & Stay Updated
